Lorenza Rimassa is Associate Professor of Medical Oncology, member of the Residency Program Directors Coordinating Committee, member of the Executive Committee and Academic Board of the PhD Program in Applied Clinical Research at Humanitas University and Head of HepatoPancreatoBiliary Oncology Unit at IRCCS Humanitas Research Hospital, in Rozzano (Milan), Italy.
She is Head of External Relations, member of the Executive Committee and Governing Board of the International Liver Cancer Association (ILCA), Lead for Biliary Tract Cancer (BTC) on the EORTC Hepatopancreatobiliary and Neuroendocrine Tumors Task Force, holds the position of Special Expert – International Trials Europe on the Hepatobiliary Task Force of the National Cancer Institute (NCI, US), and is member of the Management Committee of the COST Action CA22125 Precision medicine in biliary tract cancer” (Precision-BTC-Network).
She is co-chair of the Technical Commission of the Lombardy Oncology Network on liver and biliary tract cancer in collaboration with the Hepatogastroenterology Network (Italy), and member of the Group of Experts – Strategic Committee for the National Guideline System (SNLG), Italian Ministry of Health – Italian National Institute of Health (ISS) – DM 624712343.
She has a long-standing interest in the field of clinical and translational research for gastrointestinal cancers. She is principal investigator and member of the steering committee, data monitoring committee for national and international, phase 1–3 clinical and translational trials of new drugs and biomarkers for hepatocellular carcinoma (HCC) and cholangiocarcinoma/biliary tract cancer (CCA/BTC). She is speaker, chair, discussant, and member of the organizing and scientific committee at national and international congresses.
She has authored more than 300 articles on the development of new treatments and biomarkers for hepatobiliary cancer. She is an author of the ESMO Guideline on BTC and on HCC, a member of the Italian Inter-Society Guideline Writing Committee on HCC, of ESMO, ASCO, EASL, ILCA, and AIOM. She is Co-editor for Journal of Hepatology, Associate Editor for Liver Cancer, Therapeutic Advances in Medical Oncology, andESMO Gastrointestinal Oncology, Section Editor-in-Chief for the Disease Biomarker Section of Journal of Personalized Medicine, and an editorial board member of several journals including JHEP Reports, LiverInternational, andJournal of Hepatocellular Carcinoma.
